# name
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation

# metadata.dc.description.abstract[].value
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic
leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated
with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient
with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5%
grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced
absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median
follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In
conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high risk CLL or RT

# metadata.dc.rights[].value
cc by (c) Ortiz Maldonado, Valentín et al., 2022

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation